Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Stankiewicz

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2026
Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NOJames M Stankiewicz
Current Opinion in Clinical Nutrition and Metabolic Care|December 6, 2008
Role of iron in neurotoxicity: a cause for concern in the elderly?James M Stankiewicz, Steven D Brass
Neurology(R) Neuroimmunology & Neuroinflammation|November 24, 2019
An argument for broad use of high efficacy treatments in early multiple sclerosisJames M Stankiewicz, Howard L Weiner
Neurobiology of Aging|June 16, 2014
Iron and multiple sclerosisJames M Stankiewicz, Mohit Neema, Antonia Ceccarelli
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumabVanessa F Moreira Ferreira, David Meredith, James M Stankiewicz
Journal of Neurology|September 12, 2018
Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patientsRami Fakih, Marcelo Matiello, Tanuja Chitnis, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 29, 2012
Role of immunosuppressive therapy for the treatment of multiple sclerosisJames M Stankiewicz, Hadar Kolb, Arnon Karni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 20, 2020
A possible case of serum sickness after ocrelizumab infusionVanessa F Moreira Ferreira, Dorlan J Kimbrough, James M Stankiewicz
Multiple Sclerosis and Related Disorders|July 21, 2021
Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple SclerosisMatthew McAdams, James M Stankiewicz, Howard L Weiner, et al.
Journal of Drugs in Dermatology : JDD|September 17, 2014
Eosinophilic fasciitis-like disorder developing in the setting of multiple sclerosis therapyJohanna Sheu, Susan V Kattapuram, James M Stankiewicz, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2026
Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NOJames M Stankiewicz
Current Opinion in Clinical Nutrition and Metabolic Care|December 6, 2008
Role of iron in neurotoxicity: a cause for concern in the elderly?James M Stankiewicz, Steven D Brass
Neurology(R) Neuroimmunology & Neuroinflammation|November 24, 2019
An argument for broad use of high efficacy treatments in early multiple sclerosisJames M Stankiewicz, Howard L Weiner
Neurobiology of Aging|June 16, 2014
Iron and multiple sclerosisJames M Stankiewicz, Mohit Neema, Antonia Ceccarelli
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumabVanessa F Moreira Ferreira, David Meredith, James M Stankiewicz
Journal of Neurology|September 12, 2018
Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patientsRami Fakih, Marcelo Matiello, Tanuja Chitnis, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 29, 2012
Role of immunosuppressive therapy for the treatment of multiple sclerosisJames M Stankiewicz, Hadar Kolb, Arnon Karni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 20, 2020
A possible case of serum sickness after ocrelizumab infusionVanessa F Moreira Ferreira, Dorlan J Kimbrough, James M Stankiewicz
Multiple Sclerosis and Related Disorders|July 21, 2021
Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple SclerosisMatthew McAdams, James M Stankiewicz, Howard L Weiner, et al.
Journal of Drugs in Dermatology : JDD|September 17, 2014
Eosinophilic fasciitis-like disorder developing in the setting of multiple sclerosis therapyJohanna Sheu, Susan V Kattapuram, James M Stankiewicz, et al.
Pageof 3